TY - JOUR T1 - Multimodality treatment of malignant pleural mesothelioma JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - 2952 AU - Guntulu Ak AU - Muzaffer Metintas AU - Huseyin Yildirim AU - Hasan Batirel AU - Cumhur Sivrikoz AU - Gulden Sari AU - Egemen Doner AU - Selma Metintas AU - Emine Dundar Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/2952.abstract N2 - There is no widely accepted standart of care for patients with malignant pleural mesothelioma (MPM). Multimodality treatment protocol should be the standard approach in suitable patients and performed as a part of a trial: Biopsy proven MPM of non-sarcomatiod cell type, T1-3, N0-1, M0, patient fit for extrapleural pneumonectomy (EPP), neo-/adjuant chemotherapy, and radical hemithoracic irridation.In this study we evaluated the outcome of our patients with MPM who were treated by multimodality schedule including EPP, radical hemithoracic irridation, and cisplatin-pemetrexed/gemcitabine chemotherapy regimen.A total of 29 patients who consecutively underwent multimodality treatment schedule, 15 men, 14 women, were included. Of the patients 24 had epithelial cell type, 5 were mixed. 12 patients had stage 1 disease, 6 had II, 10 had III, 1 had IV (after surgery). Perioperative mortality (in 1 month) was 14% (4/28), mortality during multimodal therapy schedule was 18% (5/28). Patients completed multimodal Schedule were 19 (68%). Of the 19 patients completed multi-modality treatment, 11 died, 8 are alive.For all patients, 28 cases, median survival was 19 months. For 19 cases completed multimodality treatment schedule, MS was 41 months. The rate for 12, 36, 60-month survival were 89.5%, 42.1%, 31.6% respectively. For 9 cases who could not be completed multimodality tretament Schedule, median survival was 4 months.We concluded that multimodality treatment schedule in MPM is provided quite longer survival for selected cases. ER -